報價延遲最少15分鐘:2025/07/07 00:59 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.99/-2.36
|
|
企業價值
309.49M
|
| 資產負債 |
|
每股賬面淨值
2.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
4.35M
|
|
每股收益
0.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/07 00:59 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. |